Marketradar Insights: Arrowhead Pharmaceuticals Sees Buy Rating from Analysts, Price Target Set at $51.00

Strong Pipeline of siRNA Therapeutics

B.Riley Financial analyst Mayank Mamtani has reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR) and set a price target of $51.00. The analyst’s decision is driven by the company’s strong pipeline of siRNA therapeutics, which are considered dominant and differentiated across various therapeutic categories.

Regulatory Prospects Look Promising

Mayank Mamtani notes that the regulatory prospects of Arrowhead’s lead program, plozasiran, look promising, especially following the FDA approval of a peer product by IONS. This approval sets a favorable precedent for Arrowhead’s own regulatory journey, potentially benefiting from broader patient inclusion and reduced monitoring requirements in its clinical label.

Undervaluation Opportunity

The analyst underscores the undervaluation of Arrowhead’s current enterprise value relative to these high-value initiatives, suggesting a substantial opportunity for investment growth.

Recent Price Movement

ARWR’s price has also changed moderately over the past six months, ranging from $25.220 to $19.650, which is a -22.09% drop.

Company Description

Arrowhead Pharmaceuticals, Inc. operates as a biopharmaceutical company, developing medicines that treat intractable diseases by silencing the genes that cause them.